Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TT-3
- Development stage
- Preclinical
- Lead developer
- Portage Biotech
- Modality
- Small Molecules
01
Overview
TT-3 is a small molecule antagonist of the adenosine A2B receptor (A2BR) currently under development by Cyncado Therapeutics. The drug is in the IND-enabling phase, specifically targeting gut cancers. In the tumor microenvironment, high levels of adenosine contribute to immunosuppression and tumor progression; A2BR activation is particularly associated with promoting angiogenesis, metastasis, and the suppression of anti-tumor immune responses in gastrointestinal malignancies. By selectively inhibiting A2BR, TT-3 aims to disrupt these pro-tumorigenic pathways and enhance the immune system's ability to clear cancer cells.
- Other names
- TT-3TT3TT 3
02
Targets
ADORA2B (Adenosine A2B receptor)
Beyond the preview
Go deeper on TT-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TT-3.